A multi-center, double-blind, randomized, Phase II trial evaluation of the effectiveness of PR013 topical ophthalmic drops in patients aged 10 years and older with allergic conjunctivitis
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Hypochlorous acid (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Realm Therapeutics
- 04 Aug 2017 New trial record
- 02 Aug 2017 According to a Realm Therapeutics media release, the company will review efficacy data in the first half of 2018.
- 02 Aug 2017 According to a Realm Therapeutics media release, the company has submitted IND application to the U.S. FDA to initiate this trial later in 2017.